This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
Top Stories in Nephrology 2023
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
Two’s Company but Three maybe the Winner? Aldosterone Synthase Inhibition added to RASi + Flozin
Zibotentan and Flozins: Climbing to the ZENITH of nephroprotection?
The Duplex Study - Visual Abstract
Checkout the role of Sparsentan in FSGS - The Duplex Trial VA by NSMC Intern Pallavi Prasad